Summary
Abbott Laboratories reported net sales of $5.183 billion for the first quarter ended March 31, 2006, a decrease of 3.7% compared to $5.383 billion in the prior year period. This decline was primarily driven by a significant 12.4% decrease in Pharmaceutical Products sales, largely due to the amendment of a distribution agreement with Boehringer Ingelheim, which eliminated certain product sales from Abbott's revenue. Excluding these discontinued distribution activities, overall sales would have shown a modest increase of 5.2%, with growth in Diagnostics and Nutritionals segments. Despite the reported sales dip, profitability remained robust, with net earnings increasing to $864.9 million ($0.56 per diluted share) from $837.9 million ($0.53 per diluted share) in the prior year. This improvement was aided by a higher gross profit margin (58.1% vs. 53.1%), attributed to a more favorable product mix following the reduction in lower-margin co-promoted products. Research and development expenses increased to support pipeline programs, and selling, general, and administrative expenses also rose, partly due to the adoption of new accounting standards for share-based compensation. The company also announced a significant subsequent event: the acquisition of Guidant's vascular intervention and endovascular solutions businesses for $4.1 billion.
Key Highlights
- 1Net sales for the quarter were $5.183 billion, down 3.7% year-over-year, mainly due to the cessation of certain Boehringer Ingelheim product distribution.
- 2Excluding the impact of discontinued distribution, comparable sales grew by 5.2%, indicating underlying business strength in Diagnostics and Nutritionals.
- 3Net earnings increased to $864.9 million, or $0.56 per diluted share, compared to $837.9 million, or $0.53 per diluted share, in the prior year.
- 4Gross profit margin improved significantly to 58.1% from 53.1%, driven by a more favorable product mix after exiting lower-margin distribution agreements.
- 5Research and development expenses increased by 11.1% to support pipeline development, including new indications for Humira.
- 6The company adopted new accounting standards for share-based payments (SFAS 123R), impacting reported R&D and SG&A expenses.
- 7Abbott announced a significant subsequent event: the acquisition of Guidant's vascular and endovascular businesses for $4.1 billion, financed through borrowings and cash.